Tempus AI initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen initiated coverage of Tempus AI (TEM) with a Buy rating and $90 price target Tempus is a commercia-lstage technology company focused on advancing precision medicine through applications of artificial intelligence in healthcare, the analyst tells investors in a research note. The firm says the company has shown a track record of building a “strong healthcare technology business with impressive sales based on organic growth as well as complementary and synergistic acquisitions.”